Last updated on January 2020

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS).


Find a site near you

Start Over

Novartis Investigative Site

Gifu shi, Japan
7.81miles
  Connect »